In this study, based on the scenario that rituximab is eligible for reimbursement in Japan as a treatment for ITP, we investigated the cost-effectiveness of adding rituximab to splenectomy and the TPO-RA romiplostim. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.